Oxford BioDynamics raises £7.35m through placing, subscription and retail offer.
Oxford BioDynamics, a precision clinical diagnostics company leveraging its ‘EpiSwitch 3D’ genomics platform, announced the successful completion of its fundraising initiative on Friday.
Oxford Biodynamics
17 January 2025 12:18:17
Source: Sharecast
The AIM-traded firm said it had raised gross proceeds of £7.35m, comprising £7m through the placing and subscriptions announced on 15 January, and an additional £0.35m via the WRAP Retail Offer.
As part of the fundraising, Oxford said it would issue a total of 1,470,002,778 new shares at an issue price of 0.5p each, including 70,002,778 shares through the WRAP retail offer.
The board said the funds would support the company's ongoing efforts to advance its precision diagnostic solutions.
At 1140 GMT, shares in Oxford BioDynamics were down 4.76% at 0.6p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
